Skip to main content

1. Indolent lymphomas workgroup
2. Extranodal lymphomas workgroup
3. PRLG oncological cardiology workgroup
4. Mantle cell lymphomas workgroup
5. T-cell lymphomas workgroup
6. Hodgkin lymphomas workgroup
7. Aggressive lymphomas workgroup
8. Transplant group List of current studies

Ad. 1

  1. Obinutuzumab in combination with chemotherapy for induction treatment of patients with follicular lymphoma – update Ewa Paszkiewicz-Kozik.
  2. Infectious complications in FL patients treated with Obinutuzumab, Joanna Drozd-Sokołowska.
  3. Transformation of MZL to high-grade lymphoma or another lymphoma subtype – patient characteristics and treatment options, Joanna Romejko-Jarosińska.
  4. The role of hematopoietic cell autotransplantation in patients with follicular lymphoma, Anastazja Szlauer-Stefańska.
  5. Lenalidomide in the first-line treatment of indolent lymphoma patients, Ewa Lech-Marańda.
  6. Characteristics of patients with marginal zone lymphomas, evaluation of treatment methods used, Joanna Romejko-Jarosińska.
  7. Waldenstroem’s macroglobulinemia – evaluation of the treatment methods used and their effectiveness, Ewa Lech-Marańda.
  8. Orbital MZL lymphomas (from 2015), Joanna Romejko-Jarosińska, Agnieszka Giza.
  9. CMV, EBV, HHV6 viral infections in lymphoma patients, Joanna Drozd-Sokołowska, Joanna Romejko-Jarosińska.
  10. Indolent mantle cell lymphomas, Joanna Romejko-Jarosińska, Agnieszka Szerment.

Ad. 2

  1. Lymphomas of the endocrine system-a retrospective study of PLRG, Prof. Dariusz Wołowiec, Dr. Magdalena Witkowska – active study.
  2. Primary lymphomas of the kidney, Prof. Dariusz Wołowiec.
  3. Lymphomas with coexistence of ITP and/or AIHA and/or PRCA – a retrospective PLRG study, Dr. Magdalena Witkowska, Prof. Piotr Smolewski.
  4. Design of a prospective analysis of the frequency and significance of the presence of monoclonal proteins in non-Hodgkin’s lymphomas, Dr. Magdalena Olszewska-Szopa, Prof. Krzysztof Giannopoulos – active study
  5. Co-occurrence of NHL and myeloproliferation, Dr. Magdalena Olszewska-Szopa – inactive study.
  6. Efficacy and safety of conditioning with stem cell autotransplantation as consolidation treatment after induction immunochemotherapy for central nervous system lymphoma (2010-2020), Dr. Beata Ostrowska.
  7. Castleman’s disease, clinical picture, treatment, Polish experience (2005-2020), Dr. Beata Ostrowska – inactive study.
  8. A case-control analysis project of concurrent B-cell and cutaneous T-cell lymphoma – a retrospective study, Dr. Agnieszka Giza, final publication – The coexistence of Cutaneous T Cell Lymphoma and systemic B Cell Malignancies: clinical characteristic of 20 cases: a retrospective analysis of Polish Lymphoma Research Group.
  9. Primary lung lymphoma, Dr. Agnieszka Giza, Dr. Elżebita Kalicińska. The clinical landscape of primary pulmonary lymphoma in the Polish population: a multicenter retrospective study of the Polish Lymphoma Research Group (PLRG).
  10. Primary breast lymphoma, Dr. Joanna Romejko-Jarosinska.
  11. HIV-dependent lymphoma, Dr. Agnieszka Giza, Dr. hab. Monika Bociąga-Jasik, Hubert Wysogląd (Student Scientific Group).

Ad. 3

  1. Evaluation of the cardiovascular safety and anticancer efficacy of the drug pixantrone, Prof. Dariusz Wołowiec.
  2. A record of Takotsubo syndrome cases among lymphoma patients, Joanna Drozd-Sokolowska.
  3. Cardiotoxicity of Bruton’s kinase inhibitors: an observational study, Bartosz Pula.
  4. Baseline echocardiography and choice of therapy in DLBCL, Sebastian Szmit.

Ad. 4

  1. PLRG12 study “Use of acalabrutinib in patients with chronic lymphocytic leukemia or mantle cell lymphoma undergoing allogeneic stem cell transplantation,” Wojciech Jurczak.
  2. TRIANGLE study „Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma – a Randomized European MCL Network Trial”, PI prof. Jan Walewski.
  3. MCLR2 testing for elderly patients, Prof. Jan Walewski.

Planned topics:

  1. Treatment of first-line MCL lymphoma patients – a retrospective study – last 5 years.
  2. Coexistence of a second cancer with mantle cell lymphoma-a retrospective study.
  3. Indolent form : observation or treatment.
  4. TP53 evaluation.

Ad. 5

  1. Retrospective multicenter analysis of T cell lymphoma nodal forms.
  2. Use of nivolumab in the treatment of recurrent forms of mycosis fungoides granulomatosis -an observational, prospective study, Ewa Chmielowska.
  3. Mogamulizumab in the treatment of adult patients with mycosis fungoides granulomatosis or Sézary syndrome – a multicenter experience, Ewa Chmielowska.
  4. Treatment options for lymphoblastic lymphoma according to phenotypic forms/prognostic groups – location of allotransplantation, Beata Ostrowska.
  5. Brentuximab vedotin in the treatment of anaplastic lymphoma according to the drug program – reporting new cases, Katarzyna Domańska-Czyż.
  6. Blastic plasmocytoid dendritic cell neoplasm – a multicenter experience, Łukasz Targoński.
  7. Nasal-type NK/T – multicenter experience, Monika Świerkowska, Joanna Tajer.
  8. T-cell Project 2.0 collaboration proposal, reporting on all new T-NHL, Marcin Szymański.

Ad. 6

  1. Manuscript of a multicenter study: Use of salvage chemotherapy: bendamustine, gemcitabine, dexamethasone (BGD) with subsequent autologous hematopoietic cell transplantation in
  2. Hodgkin’s lymphoma patients unresponsive to ABVD treatment – a multicenter phase II study, PLRG-HL1/BURGUND.
  3. Recruitment in a multicenter trial: Use of nivolumab (N) with subsequent chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1st line therapy.
  4. Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles (RAFTING-2019), PI Jan Maciej Zaucha.
  5. NLPHL. Preparation of an abstract for PTHiT Katowice 2023.

Ad. 7

  1. Medical Research Agency Study: Rationale study – IHIT project, contractors PLRG centers – the essence of the study is to evaluate circulating DNA as an early predictor of recurrence in patients treated with R-CHOP in the first line, PI Prof. Ewa Lech-Marańda.
  2. Outcomes of Pola-BR immunochemotherapy in patients with refractory and relapsed diffuse large B-cell lymphoma with analysis of prognostic factors – data from actual clinical practice, Anna Czyż, Joanna Drozd-Sokołowska, Monika Długosz-Danecka, Ewa Lech-Marańda. * Sub-topic: NGS study in patients treated with Pola-BR to assess the presence of CHIP and search for association with treatment outcomes, Joanna Drozd-Sokołowska, Ewa Lech-Marańda.
  3. Outcomes of autoHSCT in R/R high-risk DLBCL (primary resistance, relapse up to 12 m, double hit/double expressor, high IPI in relapse) – together with the SCT Section of the PLRG – analysis of outcomes in the context of the new registration indication for CAR-T , T. Czerw, A. Czyż.

Ad. 8

  1. Excellent survival after allogeneic haematopoietic cell transplantation in patients with relapsed or refractory Hogdkin lymphoma in the era of immunotherapy. Anna Czyż, Kateryna Filonenko, Anna Kopińska, Grzegorz Helbig, Anna Łojko, Lidia Gil, Małgorzata Ociepa, Tomasz Czerw, Maciej Majcherek, Tomasz Wróbel, Sylwia Bartyzel, Patrycja Mensah-Glanowska, Agnieszka Piekarska, Maria Bieniaszewska, Sebastian Giebel, Jan Maciej Zaucha, EBMT 2023 Poster.
  2. Autologous hematopoietic cell transplantation for marginal zone lymphomas – multicenter analysis by the Polish Lymphoma Research Group, Joanna Drozd-Sokołowska, Małgorzata Sobczyk-Kruszelnicka, Anna Kopińska, Elżbieta Sienkiewicz, Joanna Romejko-Jarosińska, Mariola Sędzimirska, Agnieszka Tomaszewska, Kateryna Filonenko, Grzegorz Helbig, Jan Maciej Zaucha, Grzegorz Basak, Sebastian Giebel, Tomasz Czerw, EBMT 2023 Poster. In collaboration with the indolent lymphoma section.
  3. Allo-HCT in PTCL, Małgorzata Sobczyk-Kruszelnicka (Gliwice), Tomasz Czerw, Joanna Drozd-Sokołowska, Patrycja Mensah-Glanowska, Agnieszka Piekarska, Anna Łojko-Dankowska, Anna Czyż, Sebastian Giebel.
  4. Autotransplantation of hematopoietic cells in patients with lobular lymphoma, Anastasia Szlauer-Stefańska.
  5. Treatment outcome of primary mediastinal B cell lymphoma after high dose chemotherapy with autologous hematopoietic cell transplantation. A study of the Polish Lymphoma Research Group, Joanna Romejko-Jarosińska, Ewa Paszkiewicz-Kozik, Małgorzata Krawczyk-Kuliś, Patrycja Mensah-Glanowska, Łukasz Targoński, Agnieszka Giza, Tomasz Czerw, Katarzyna Domańska-Czyż, Kseniya Kviatkouskaya, Paulina Magda, Włodzimierz Mendrek, Beata Ostrowska, Maria Saduś-Wojciechowska, Sebastian Giebel, Jan Walewski, EBMT Poster.
  6. Autologous Hematopoietic Cell Transplantation in the Treatment of High Grade B Cell Lymphoma, Joanna Romejko-Jarosińska.
  7. Autologous hematopoietic cell transplantation with or without total body irradiation in newly diagnosed mantle cell lymphoma patients. A multicenter real-world analysis by Polish Lymphoma Research Group, Michał Szymczyk1*, Sebastian Giebel2, Wojciech Jurczak3, Joanna Romejko-Jarosińska1, Monika Długosz-Danecka3, Katarzyna Krawczyk4, Agnieszka Giza4, Tomasz Czerw2, Anna Czyż5, Anna Kopińska6, Joanna Drozd-Sokołowska7, Tomasz Wróbel5, Edyta Subocz8, Kazimierz Halaburda9, Ewa Chmielowska10, Włodzimierz Osiadacz1, Barbara Brzeska1, Ewa Paszkiewicz-Kozik1, Mieczysław Komarnicki11 and Jan Walewski1.